ERBB2 and breast cancer: Recently, the advent of targeted therapies that include tyrosine kinase inhibitors (TKIs), such as lapatinib and anti-HER2 antibodies (such as trastuzumab), have considerably improved the overall survival and time-to-disease progression values in HER2+ breast cancer patients3.